Additionally, a previous clinical trial found that the PFS of Osimertinib combined with Bevacizumab was shorter than that of Osimertinib alone in NSCLC patients with the EGFR T790M mutation (54), and we found the same result in an untreated population. This evidence concerns the gene EGFR and non-small cell lung carcinoma.